Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

TheFly reported connected June 9 that Truist Securities initiated sum of ZYME with a Buy standing and a $28 terms target, down from $40. The steadfast highlighted ZYME arsenic a balanced concern opportunity, supported by its royalty-based concern exemplary and expanding oncology pipeline that could supply semipermanent maturation potential. Truist besides pointed to pipeline assets, including Pasritamig successful metastatic castration-resistant prostate cancer, arsenic imaginable contributors owed to upcoming objective milestones.

Separately, connected June 14, Zymeworks Inc. (NASDAQ:ZYME) presented updated objective findings from the dose-escalation signifier of its ongoing Phase 1 proceedings assessing ZW191, an antibody-drug conjugate targeting folate receptor alpha. The information were presented astatine the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. Results showed encouraging anti-tumor enactment successful platinum-resistant ovarian crab patients crossed antithetic FRalpha look levels. ZW191 achieved a confirmed nonsubjective effect complaint of 78.6% successful FRalpha-positive patients and 47.4% successful FRalpha-negative patients crossed evaluated dose levels. Median duration of effect had not yet been reached, portion median progression-free endurance was 7.6 months crossed ovarian and endometrial crab groups. Dose optimization enrollment was completed, with tolerability results supporting further objective development.

Zymeworks Inc. (NASDAQ:ZYME) is simply a clinical-stage biotechnology institution processing next-generation crab therapies, including multispecific antibodies and antibody-drug conjugates (ADCs).

While we admit the imaginable of ZYME arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.